Despite planting seeds for decades, Singapore has yet to blossom into a global hub for biotechs. A new wave of international biopharmas setting up shop in the country and an influx of sophisticated, global biotech investors could change that.
Lattice Semiconductor CEO Jim Anderson Joins the Board of Directors as the Company Enters into Customer Deployments of Private 5G and Open RAN Networks
The funding will be used as working capital to further develop the company’s innovative digital cross-border trade and financial services enabled by trusted credentials.
The pandemic has brought the spotlight onto the healthcare and biomedical sectors, driving unprecedented enthusiasm in the relatively unknown field of mRNA innovations, and bolstering growth in digital health. Yet, the silver lining has dulled investors’ sentiments post-COVID. Increasingly, investors have become more cautious against macroeconomic headwinds, and many are expecting a correction in company valuations across all sectors.
Reflecting on the year and new developments in Q4
The latest round of funding was led by Patient Square Capital and included participation from EDBI, PS Capital, Alafi Capital, and NRW.BANK, as well as other existing investors.
Fresh investment from prominent investors will propel Fazz into a new season of growth and further accelerate the future of Business Finance in Southeast Asia.
Dive into China and Southeast Asia’s agrifood landscape, and what the future holds
Subscribe to our quarterly e-Newsletter, The Upside to find out what’s shaping the future industries of Singapore and the region.
Investing in high-growth technologies that shape the future economic pillars of Singapore since 1991.
